Edgar Filing: CORE LABORATORIES N V - Form 8-K

CORE LABORATORIES N V Form 8-K November 08, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 8, 2006 (November 7, 2006)

CORE LABORATORIES N.V.

(Exact name of registrant as specified in its charter)

001-14273

(Commission File Number)

The Netherlands (State or other jurisdiction of incorporation or organization)

Not Applicable (I.R.S. Employer Identification No.)

Herengracht 424 1017 BZ Amsterdam The Netherlands (Address of principal executive offices)

Not Applicable (Zip Code)

Registrant's telephone number, including area code: (31-20) 420-3191

Check the appropriate below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

Edgar Filing: CORE LABORATORIES N V - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 8.01 Other Events.

On November 7, 2006, Core Laboratories N.V. issued a press release announcing revisions to previously issued earnings guidance for its 2006 fourth fiscal quarter and fiscal year 2007. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Press release issued on November 7, 2006*

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Securities Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By

Core Laboratories N.V.

Dated: November 8, 2006

/s/ Richard L. Bergmark Richard L. Bergmark Chief Financial Officer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> CORE LABORATORIES N.V. EXHIBIT INDEX TO FORM 8-K

Edgar Filing: CORE LABORATORIES N V - Form 8-K

EXHIBIT NO. ITEM

99.1 Press release issued on November 7, 2006*

* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Securities Act of 1934, as amended.